Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best strong buy healthcare stocks to buy now. On July 22, Morgan Stanley raised the firm’s price target on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to $150 from $148, keeping an Overweight rating on the shares.

The firm gave the rating ahead of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) reporting its Q2 2025 results on July 30.

Morgan Stanley expects Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report $630 million in Ingrezza sales for the quarter, aligning with expectations. It expects Crenessity sales to be around $20 million, slightly below the $23M consensus.

The firm also told investors in its preview that it continues to see “under-appreciated value in 2H and beyond.”

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a biopharmaceutical company with a focus on neuroscience. It is involved in the research and development, sale, and commercialization of pharmaceuticals that treat neuroendocrine, neurological, and neuropsychiatric disorders.

The company’s product portfolio includes treatments for chorea associated with Huntington’s disease, tardive dyskinesia, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.

While we acknowledge the potential of NBIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.